Immune-Onc: An Song and Adrian Jubb
Immune-Onc Therapeutics has announced the hiring of two executives and securement of Series B funding worth $33m. Both appointments arrive with experience of working at Roche subsidiary, Genentech – Adrian Jubb arrives as chief medical officer, after having previously spent three years as medical director at Genentech, and An Song will move to the company as vice president and head of early development, after over a decade with Genentech.
Immune-Onc is still at the early stages of breaking out as a biotech, and plans to use the money garnered from its financing round to take its translational research into the clinic. As the name suggests, the biotech will focus on developing biologic immunotherapy treatments for cancer.
Charlene Liao, co-founder, president and chief executive officer of Immune-Onc, said: “Adrian and An’s decades of industry expertise in drug development will be critical in advancing our mission to develop novel biotherapeutics for hard-to-treat cancers.”
In particular, Song was noted in the announcement as having contributed to the regulatory approvals of a number of Roche’s commercially successful products, such as Rituxan (rituximab), Avastin (bevacizumab), and Herceptin (trastuzumab).
